IBS, the Microbiome and the Potential of Probiotics:
FDA authorizes IND to study the effects of DS-01 (Daily Synbiotic) on patients living with IBS
Posted on Tuesday, November 17, 2020, at 4:57 AM
Cramping. Abdominal pain. Bloating, gas, and diarrhea. These are unpleasant words to read and even more troublesome to endure physically. But that’s the day-to-day experience of those who suffer from irritable bowel syndrome, or IBS, the most common gastrointestinal condition worldwide. IBS affects an estimated 10-15% of the U.S. population and nearly 12% of all...